FY2025 · ended Dec 31, 2025 · Revenue $25.42M, -87.9% YoY · Filed Feb 26, 2026
Entrada Therapeutics, Inc. (TRDA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $25.4 million and a net loss of $143.8 million. Free cash flow was -$129.6 million. As of Jun 30, 2026 it held $99.3 million in cash and investments and $48.5 million in total debt.
Revenue (TTM)
$4.69M
-94.1% vs year-ago TTM
Net income (TTM)
$-165.78M
-126.0% vs year-ago TTM
Operating cash flow (TTM)
$-134.67M
-8.7% vs year-ago TTM
Free cash flow (TTM)
$-135.00M
-6.7% vs year-ago TTM
EPS (TTM)
$-3.97
-127.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
38.28M
+1.8% vs prior year
Net cash
$50.74M
as of Jun 30, 2026
Operating margin
-3767.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TRDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1689375
- Former names
- CycloPorters, Inc. (until Nov 10, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | — | — |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M | -$51.2M |
| Diluted EPS | -$3.47 | $1.68 | -$0.20 | -$3.02 | -$8.16 |
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M |
| Stockholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M |
| Cash and investments | $90.4M | $101.2M | $67.6M | $45.2M | $291.1M |
| Total debt | $50.9M | $59.2M | $68.2M | $25.9M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 10, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 19, 2026 | May 18, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 472 Entrada Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.